Don't Expect the Antibiotic Plazomicin to Be Added to Your Hospital Formulary

You'll see the new aminoglycoside, plazomicin (Zemdri, ZEM-dree), promoted for carbapenem-resistant Enterobacteriaceae (CRE).

It works like other aminoglycosides and has the same side effects...nephrotoxicity, ototoxicity, etc.

The difference is that plazomicin isn't as affected by aminoglycoside-modifying enzymes...the most common cause of aminoglycoside resistance to E. coli and other Enterobacteriaceae.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote